Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.
Jun Ma(Shanghai Institute of Technology), Jibin Li(State Key Laboratory of Pollution Control and Resource Reuse), Xiaozhong Chen(Tokyo Institute of Technology), G. Hu(Dalian University), Shubin Hong(Sun Yat-sen University), Yawei Yuan(Ruijin Hospital), Ying Huang(Sun Yat-sen University), Ying Sun(Key Laboratory of Guangdong Province), Feng Jin(China Medical University), Kunyu Yang(Macau University of Science and Technology), Xu Liu(Sun Yat-sen University), Ning Zhang(First People's Hospital of Foshan), Xiaodong Zhu(Guangxi Medical University), Wei‐Han Hu(Sun Yat-sen University), Chuanben Chen(Fujian Medical University), Guorong Zou(Panyu District Central Hospital), Ye‐Lin Liang(Sun Yat-sen University), Liangfang Shen(Central South University), Hongyun Zhao(Chinese Academy of Sciences), Fang‐Yun Xie(Sun Yat-sen University)
Cited by 17
Related Papers
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
A Metagenomic Approach to Characterization of the Vaginal Microbiome Signature in Pregnancy
|PLoS ONE|2012|703
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma
|Cell Research|2020|483
Long Noncoding RNA FAM225A Promotes Nasopharyngeal Carcinoma Tumorigenesis and Metastasis by Acting as ceRNA to Sponge miR-590-3p/miR-1275 and Upregulate ITGB3
|Cancer Research|2019|423
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline
|Journal of Clinical Oncology|2021|393